Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
12/30/2024
TEVIMBRA Approved in the U.S. as First-line Treatment of G/GEJ in Com...
12/30/2024
India Deepens Ties with Chinese Biotech: Cipla and Mankind Lead the W...
12/30/2024
TJ Bio Submits BLA for Genexine's Long-Acting Pediatric Growth Hormone...
12/30/2024
2025 Forecast: What Can AstraZeneca's China Probes Teach Other Biophar...
12/27/2024
Review of China's Hospital Drug Market: Strong Competition Amid Slight...
12/27/2024
China's Commercial Health Insurance: Growth Trends and Challenges in C...
12/27/2024
Collaborative Governance Mechanism for Healthcare, Medical Insurance, ...
12/27/2024
Recent Executive Moves
12/26/2024
Alphamab Initiates Phase I/II Trial for HER2 ADC Bispecific and PD-L1 ...
12/24/2024
Roche's Lunsumio (Mosunetuzumab) Gains NMPA Approval for r/r Follicula...
12/24/2024
State Council Moves to Advance Pharma Reforms and Regulatory Streamlin...
12/24/2024
WuXi Biologics to Divest Advanced Therapies Unit Amid U.S. Restriction...
12/23/2024
Sanofi Acquires Rights to Cytokinetics's Aficamten in Greater China
12/23/2024
MSD Finalizes Exclusive Global License Deal for Anti-PD-1 LM-299
12/23/2024
Roch Secures Chinese Approval of Lunsumio (Mosunetuzumab) for r/r Fol...
12/23/2024
RAPT Thera and Jemincare Enter License Deal for Novel Long-Acting an...
12/20/2024
China Licenses First Wholly Foreign-Owned Third-Grade General Hospital...
12/20/2024
Recent Executive Moves
12/19/2024
Palleon and Henlius Collaborate to Advance Glycan Editing for Autoimmu...
12/19/2024
BMS China Regains Rights to GPC3 Targeted Drug ABZ-706 in Greater Chin...
12/18/2024
Merck and Hansoh Enter into Global License Deal for Investigational Or...
12/18/2024
BMS and Fangzhou Forge Strategic Alliance to Advance Digital Healthcar...
12/17/2024
Eli Lilly's Alzheimer's Drug Donanemab Secures Approval in China
12/16/2024
Everest Medicines Announces Acceptance of the NDA for VELSIPITY
12/16/2024
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Col...
12/16/2024
Mabwell Plans Hong Kong Dual Listing Amid Shifting Market Dynamics
12/16/2024
Sinopharm's Mpox Vaccine Gains Clinical Trial Approval in China
12/15/2024
HUTCHMED Announces Breakthru Designation in China for ORPATHYS and TA...
12/15/2024
National Healthcare Security Work Conference Highlights Progress and S...
12/13/2024
RemeGen Unveils Phase III Study Results of Disitamab Vedotin in HER2-P...
Page:
12
/
356
Total number of articles:
10656
:
[First]
[<<]
[10]
[11]
[12]
[13]
[14]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit